Previous 10 | Next 10 |
2023-11-07 16:04:47 ET More on Personalis Personalis: Collaborations Should Ignite Growth Narrative Personalis Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Personalis Historical earnings data for Personalis For further details see: ...
Increased third quarter revenue 23% to $18.2 million and increased full year guidance Presented data supporting NeXT Personal’s market leading sensitivity for cancer recurrence detection Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision on...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Personalis Inc. (PSNL) is expected to report $-0.54 for Q3 2023
NeXT Personal Dx is an ultra-sensitive test for detecting cancer from a blood sample Clinical data from groundbreaking TRACERx lung cancer study demonstrates significant sensitivity and lead time improvements in detecting cancer Personalis, Inc . (Nasdaq: PSNL), a leader i...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2023 financial results on Tuesday, November 7, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p...
NeXT Personal ® ctDNA assay shown to be more sensitive and predictive of clinical outcomes in early-stage lung cancer patients Demonstrates importance of an ultra-sensitive ctDNA approach Personalis, Inc . (Nasdaq: PSNL), a leader in precision oncology, today announ...
Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc . (Nasdaq: PSNL), a leader...
2023-09-06 08:27:34 ET Summary Personalis is a small-cap stock specializing in cancer genomics, with an advanced cancer diagnostics platform. The company reported significant losses in Q2 earnings but maintains a robust financial standing and expects future revenue growth. Per...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the 21 st Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023 at 4:55 p.m. Eastern Time in New York, NY at the Sheraton...
News, Short Squeeze, Breakout and More Instantly...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate virtually at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 13, 2024. About Personalis, Inc. At Personalis, ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...